Therefore, the identification of ghrelin regulatory pathways on eNOS activation may give insights about the therapeutic potential of ghrelin to correct endothelial dysfunction in patients with cardiovascular disease and diabetes [198]. This evidence concerns the gene GHRL and endothelial dysfunction.